Drug Trial Radar · NCT01867164
A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis
Last checked: Nov 19, 2026Latest source record: Dec 24, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Dec 2007
Primary completion
Dec 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- Janssen-Cilag, S.A.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 3, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this comparative study is to evaluate the efficacy of an ovule with triple active agents (terconazole, clindamycin and fluocinolone) versus another ovule with triple active agents (nystatin, metronidazole and fluocinolone) in the treatment of symptoms caused by the presence of vaginitis (inflammation of the vagina) or bacterial vaginosis (polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli).
Conditions
- Vaginitis
- Infectious Vaginosis
Interventions
Gynoclin VDrug
One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
Vagitrol VDrug
One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Presence or Absence of Symptoms 3 Days After TreatmentTime frame: 3 days after treatment (Day 7 for Gynoclin V or Day 13 for Vagitrol V)
- Percentage of Participants With Presence or Absence of Symptoms 8 Days After TreatmentTime frame: 8 days after treatment (Day 12 for Gynoclin V or Day 18 for Vagitrol V)
- Percentage of Participants With the Presence of Microorganisms (Single-celled, Tiny Organisms That Include Fungi, Bacteria, Viruses) 3 Days After TreatmentTime frame: 3 days after treatment (Day 7 for Gynoclin V or Day 13 for Vagitrol V)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Mexico City, Mexico
Site not named
DF, Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.